- Home
- SVII vs VXRT Comparison
SVII vs VXRT Comparison
Compare SVII & VXRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVII
- VXRT
- Stock Information
- Founded
- SVII 2021
- VXRT N/A
- Country
- SVII United States
- VXRT United States
- Employees
- SVII N/A
- VXRT N/A
- Industry
- SVII Blank Checks
- VXRT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SVII Finance
- VXRT Health Care
- Exchange
- SVII Nasdaq
- VXRT Nasdaq
- Market Cap
- SVII 116.6M
- VXRT 119.0M
- IPO Year
- SVII 2022
- VXRT N/A
- Fundamental
- Price
- SVII $11.75
- VXRT $0.46
- Analyst Decision
- SVII
- VXRT Strong Buy
- Analyst Count
- SVII 0
- VXRT 2
- Target Price
- SVII N/A
- VXRT $3.00
- AVG Volume (30 Days)
- SVII 4.7K
- VXRT 9.5M
- Earning Date
- SVII 01-01-0001
- VXRT 08-07-2025
- Dividend Yield
- SVII N/A
- VXRT N/A
- EPS Growth
- SVII N/A
- VXRT N/A
- EPS
- SVII 0.25
- VXRT N/A
- Revenue
- SVII N/A
- VXRT $47,395,000.00
- Revenue This Year
- SVII N/A
- VXRT N/A
- Revenue Next Year
- SVII N/A
- VXRT N/A
- P/E Ratio
- SVII $47.38
- VXRT N/A
- Revenue Growth
- SVII N/A
- VXRT 433.43
- 52 Week Low
- SVII $11.06
- VXRT $0.29
- 52 Week High
- SVII $11.90
- VXRT $1.07
- Technical
- Relative Strength Index (RSI)
- SVII 54.77
- VXRT 44.57
- Support Level
- SVII $11.50
- VXRT $0.54
- Resistance Level
- SVII $11.78
- VXRT $0.60
- Average True Range (ATR)
- SVII 0.07
- VXRT 0.09
- MACD
- SVII -0.00
- VXRT -0.02
- Stochastic Oscillator
- SVII 78.86
- VXRT 6.92
About SVII Spring Valley Acquisition Corp. II
Spring Valley Acquisition Corp II is a blank check company.
About VXRT Vaxart Inc
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.